Company profile
Ticker
ALDX
Exchange
Website
CEO
Dr. Todd C. Brady M.D., Ph.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Aldexa Therapeutics, Inc., Neuron Systems Inc
SEC CIK
Corporate docs
Subsidiaries
Helio Vision, LLC • Helio Vision Germany GmbH ...
ALDX stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
18 Nov 24
10-Q
2024 Q3
Quarterly report
7 Nov 24
8-K
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
3 Oct 24
8-K
Entry into a Material Definitive Agreement
2 Oct 24
8-K
Departure of Directors or Certain Officers
3 Sep 24
8-K
Regulation FD Disclosure
8 Aug 24
424B5
Prospectus supplement for primary offering
1 Aug 24
8-K
Entry into a Material Definitive Agreement
1 Aug 24
10-Q
2024 Q2
Quarterly report
1 Aug 24
8-K
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
20 Jun 24
Transcripts
ALDX
Earnings call transcript
2022 Q4
9 Mar 23
ALDX
Earnings call transcript
2022 Q3
10 Nov 22
ALDX
Earnings call transcript
2022 Q2
5 Aug 22
ALDX
Earnings call transcript
2022 Q1
5 May 22
ALDX
Earnings call transcript
2021 Q4
17 Mar 22
ALDX
Earnings call transcript
2021 Q3
28 Oct 21
ALDX
Earnings call transcript
2021 Q2
5 Aug 21
ALDX
Earnings call transcript
2021 Q1
6 May 21
ALDX
Earnings call transcript
2020 Q4
11 Mar 21
ALDX
Earnings call transcript
2020 Q3
5 Nov 20
Latest ownership filings
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Nov 24
4
Nancy Miller-Rich
21 Oct 24
3
Michael Alfieri
10 Sep 24
4
Stephen Machatha
14 Aug 24
4
Bruce Greenberg
14 Aug 24
144
Notice of proposed sale of securities
12 Aug 24
144
Notice of proposed sale of securities
12 Aug 24
4
RICHARD DOUGLAS
6 Jun 24
4
MARTIN JOSEPH JOYCE
6 Jun 24
4
Neal Walker
6 Jun 24
Financial summary
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 68.12 mm | 68.12 mm | 68.12 mm | 68.12 mm | 68.12 mm | 68.12 mm |
Cash burn (monthly) | 969.90 k | 6.27 mm | 5.38 mm | 4.14 mm | 2.66 mm | 2.56 mm |
Cash used (since last report) | 4.53 mm | 29.28 mm | 25.13 mm | 19.32 mm | 12.42 mm | 11.94 mm |
Cash remaining | 63.59 mm | 38.84 mm | 42.99 mm | 48.80 mm | 55.70 mm | 56.18 mm |
Runway (months of cash) | 65.6 | 6.2 | 8.0 | 11.8 | 21.0 | 22.0 |
Institutional ownership, Q3 2024
61.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 113 |
Opened positions | 20 |
Closed positions | 10 |
Increased positions | 40 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 194.04 bn |
Total shares | 36.70 mm |
Total puts | 107.30 k |
Total calls | 195.50 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Perceptive Advisors | 9.28 mm | $50.00 bn |
Knoll Capital Management | 5.48 mm | $29.51 bn |
Vanguard | 3.76 mm | $20.27 bn |
BlackRock | 3.73 mm | $20.13 bn |
Kennedy Capital Management | 1.88 mm | $10.14 bn |
Geode Capital Management | 1.11 mm | $6.01 bn |
STT State Street | 973.91 k | $5.25 bn |
Eagle Asset Management | 709.52 k | $3.92 bn |
IVZ Invesco | 656.51 k | $3.54 bn |
Dimensional Fund Advisors | 604.04 k | $3.26 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Aug 24 | Stephen Machatha | Common Stock | Sell | Dispose S | No | No | 4.7363 | 16,041 | 75.97 k | 236,771 |
12 Aug 24 | Bruce Greenberg | Common Stock | Sell | Dispose S | No | No | 4.7363 | 10,834 | 51.31 k | 126,382 |
4 Jun 24 | Gary M. Phillips | Stock Option Common Stock | Grant | Acquire A | No | No | 4.09 | 2,604 | 10.65 k | 2,604 |
4 Jun 24 | Gary M. Phillips | Stock Option Common Stock | Grant | Acquire A | No | No | 4.09 | 3,473 | 14.20 k | 3,473 |
4 Jun 24 | Gary M. Phillips | Stock Option Common Stock | Grant | Acquire A | No | No | 4.09 | 40,282 | 164.75 k | 40,282 |
4 Jun 24 | Miller-Rich Nancy | Stock Option Common Stock | Grant | Acquire A | No | No | 4.09 | 1,736 | 7.10 k | 1,736 |
4 Jun 24 | Miller-Rich Nancy | Stock Option Common Stock | Grant | Acquire A | No | No | 4.09 | 40,282 | 164.75 k | 40,282 |
Press releases
Aldeyra, UnitedHealth Group Incorporated, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
9h ago
Aldeyra Therapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
2w ago
Aldeyra, UnitedHealth Group Incorporated, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
1mo ago
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
2mo ago